In AD pathology, the σ2 receptor interacts with PGRMC1 and LDLR to block AβO from binding neuronal synapses and regulates cholesterol homeostasis [44], and acts as a novel biomarker for AD diagnose and drug development [160]. Here, PGRMC1 is linked to Alzheimer disease.